Status:
RECRUITING
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer
Lead Sponsor:
Du Juan
Conditions:
Locally Advanced Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systemati...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed pancreatic cancer;
- ECOG performance no more than 2;
- Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines;
- No previous anti-tumor therapy；
- Able and willing to provide a written informed consent;
Exclusion
- 1\. Prior anti-tumor therapy of any kind; 2. Severe infection (\>NCI CTC grade 2); 3.Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women.
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06494514
Start Date
April 1 2024
End Date
April 1 2027
Last Update
July 10 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
FirstNanjingMU
Nanjing, Jiangsu, China, 025
2
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China, 025